Specifically, Li et al., 2022 [235], included 50 post-operative HER2 breast cancer patients registered to receive trastuzumab in combination with pertuzumab, without a diagnosis of severe cardiac complications and/or hypertension, thoracic abnormalities or endocrine system diseases. The gene discussed is ERBB2; the disease is breast cancer.